Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liraglutide - 4Moving Biotech

Drug Profile

Liraglutide - 4Moving Biotech

Alternative Names: 4P 004

Latest Information Update: 14 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INSERM; Sorbonne University
  • Developer 4Moving Biotech; 4P-Pharma
  • Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Antirheumatics; Glucagon-like peptides; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Osteoarthritis

Most Recent Events

  • 10 Nov 2023 4Moving Biotech plans a phase IIb trial in Osteoarthritis (Intra-articular)
  • 31 Oct 2023 4Moving Biotech completes a phase I trial in Osteoarthritis in Belgium (Intra-articular) (NCT05419856)
  • 20 Oct 2023 4Moving Biotech completes enrolment in its phase I LASARE trial for Osteoarthritis in Belgium (NCT05419856)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top